Mitsugu Kochi

1.5k total citations · 1 hit paper
75 papers, 1.1k citations indexed

About

Mitsugu Kochi is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Mitsugu Kochi has authored 75 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Pulmonary and Respiratory Medicine, 39 papers in Oncology and 23 papers in Surgery. Recurrent topics in Mitsugu Kochi's work include Gastric Cancer Management and Outcomes (44 papers), Colorectal Cancer Treatments and Studies (32 papers) and Metastasis and carcinoma case studies (22 papers). Mitsugu Kochi is often cited by papers focused on Gastric Cancer Management and Outcomes (44 papers), Colorectal Cancer Treatments and Studies (32 papers) and Metastasis and carcinoma case studies (22 papers). Mitsugu Kochi collaborates with scholars based in Japan and United States. Mitsugu Kochi's co-authors include Masashi Fujii, Tadatoshi Takayama, Teruo Kaiga, Yuichi Kasakura, Fumiro Mochizuki, Masahiro Takeuchi, Wataru Ichikawa, Yasuhiro Kodera, Motoo Yamagata and Akinori Takagane and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Surgery and Annals of Oncology.

In The Last Decade

Mitsugu Kochi

71 papers receiving 1.0k citations

Hit Papers

Addition of Docetaxel to ... 2019 2026 2021 2023 2019 50 100 150 200 250

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mitsugu Kochi Japan 16 748 446 364 336 103 75 1.1k
Norisuke Nakayama Japan 16 642 0.9× 331 0.7× 327 0.9× 347 1.0× 84 0.8× 57 870
Jae-Seok Min South Korea 15 827 1.1× 433 1.0× 487 1.3× 262 0.8× 136 1.3× 69 1.2k
Mao-Chih Hsieh Taiwan 16 453 0.6× 342 0.8× 216 0.6× 181 0.5× 69 0.7× 29 752
Takeo Kosaka Japan 15 420 0.6× 322 0.7× 208 0.6× 219 0.7× 95 0.9× 85 769
Toshiyuki Tanahashi Japan 14 468 0.6× 277 0.6× 235 0.6× 219 0.7× 92 0.9× 52 714
Seiichi Takagi Japan 7 1.4k 1.9× 574 1.3× 671 1.8× 723 2.2× 151 1.5× 15 1.7k
André M. Murad Brazil 10 944 1.3× 372 0.8× 237 0.7× 736 2.2× 109 1.1× 21 1.2k
Kosei Miyashita Japan 3 1.3k 1.7× 520 1.2× 590 1.6× 689 2.1× 150 1.5× 6 1.5k
Teiji Naka Japan 17 384 0.5× 357 0.8× 190 0.5× 259 0.8× 146 1.4× 37 804
Toshikazu Akiya Japan 8 1.5k 2.0× 583 1.3× 664 1.8× 852 2.5× 150 1.5× 12 1.7k

Countries citing papers authored by Mitsugu Kochi

Since Specialization
Citations

This map shows the geographic impact of Mitsugu Kochi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mitsugu Kochi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mitsugu Kochi more than expected).

Fields of papers citing papers by Mitsugu Kochi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mitsugu Kochi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mitsugu Kochi. The network helps show where Mitsugu Kochi may publish in the future.

Co-authorship network of co-authors of Mitsugu Kochi

This figure shows the co-authorship network connecting the top 25 collaborators of Mitsugu Kochi. A scholar is included among the top collaborators of Mitsugu Kochi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mitsugu Kochi. Mitsugu Kochi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Satake, Hironaga, Akihito Tsuji, Chihiro Tanaka, et al.. (2022). Tumor response of FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: The subgroup-analysis of DEEPER trial (JACCRO CC-13).. Journal of Clinical Oncology. 40(4_suppl). 109–109. 1 indexed citations
2.
Tsuji, Akihito, Hisatsugu Ohori, Tatsuro Yamaguchi, et al.. (2021). The randomized phase II study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as the first-line treatment in metastatic colorectal cancer with RAS wild-type tumors: The DEEPER trial (JACCRO CC-13).. Journal of Clinical Oncology. 39(15_suppl). 3501–3501. 10 indexed citations
3.
4.
Sunakawa, Yu, Kaoru Mogushi, Heinz‐Josef Lenz, et al.. (2018). Tumor Sidedness and Enriched Gene Groups for Efficacy of First-line Cetuximab Treatment in Metastatic Colorectal Cancer. Molecular Cancer Therapeutics. 17(12). 2788–2795. 3 indexed citations
6.
Kakeji, Yoshihiro, Yasuhiro Kodera, Kazuhiro Yoshida, et al.. (2015). Pre-planned feasibility and safety analyses of docetaxel/S-1 combination in a phase III study comparing docetaxel/S-1with S-1 alone as postoperative adjuvant chemotherapy for stage III gastric cancer (JACCRO GC-07).. Journal of Clinical Oncology. 33(15_suppl). e15000–e15000. 1 indexed citations
7.
Kochi, Mitsugu, et al.. (2014). Radiochemotherapy for esophageal squamous cell carcinoma in elderly patients.. PubMed. 61(134). 1617–22. 5 indexed citations
8.
Kochi, Mitsugu, et al.. (2014). Phase II Study of Neoadjuvant Chemotherapy With S-1 and CDDP in Patients With Lymph Node Metastatic Stage II or III Gastric Cancer. American Journal of Clinical Oncology. 40(1). 17–21. 11 indexed citations
9.
Kochi, Mitsugu, et al.. (2013). Differing deregulation of HER2 in primary gastric cancer and synchronous related metastatic lymph nodes. Diagnostic Pathology. 8(1). 191–191. 32 indexed citations
10.
Tsuji, Akihito, Masato Nakamura, Yu Sunakawa, et al.. (2013). A Phase II Study of Cetuximab and MFOLFOX6 in MCRC Including Prospective Early Tumor Shrinkage Analysis (JACCRO-CC05). Annals of Oncology. 24. iv94–iv94. 4 indexed citations
11.
Kochi, Mitsugu, Katsuhisa Enomoto, Isamu Yoshitake, et al.. (2013). Annual Report for the Department of Surgery in 2012 (The sixth report). 72(5). 274–278.
12.
Kochi, Mitsugu, Yuji Akiyama, Tatsuya Aoki, et al.. (2013). FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study. Cancer Chemotherapy and Pharmacology. 72(5). 1097–1102. 9 indexed citations
13.
Kochi, Mitsugu, et al.. (2011). A case of complete response to S-1 plus CDDP in early-stage mucosal esophageal cancer.. PubMed. 31(3). 1019–22. 2 indexed citations
14.
Fujii, Masashi, Mitsugu Kochi, & Tadatoshi Takayama. (2010). Recent advances in chemotherapy for advanced gastric cancer in Japan. Surgery Today. 40(4). 295–300. 31 indexed citations
15.
Takayama, Tadatoshi, Hideki Masuda, Mitsugu Kochi, et al.. (2008). Bioresorbable Membrane to Reduce Postoperative Small Bowel Obstruction in Patients With Gastric Cancer. Annals of Surgery. 247(5). 766–770. 53 indexed citations
16.
Sakurai, Kenichi, Katsuhisa Enomoto, Akira Sezai, et al.. (2008). Annual Report of The Department of Surgery in 2007. 67(5). 281–286. 1 indexed citations
17.
Yoshida, Nao, et al.. (2008). A CASE OF PROTEIN-LOOSING GASTROENTEROPATHY CAUSED BY DOUBLE GASTRIC CANCER. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association). 69(2). 365–369.
18.
Kochi, Mitsugu, et al.. (2008). SPONTANEOUS REGRESSION OF ADVANCED COLON CANCER-CASE REPORT-. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association). 69(7). 1717–1720. 2 indexed citations
19.
20.
Mochizuki, Fumiro, Masashi Fujii, Yuichi Kasakura, et al.. (2000). Analysis of Recurrence in Early Gastric Cancer. Multivariate Analysis of Risk Factors Using Logistic Regression.. The Japanese Journal of Gastroenterological Surgery. 33(4). 440–447. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026